Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study

BACKGROUND: In premenopausal women, treatment with direct oral factor Xa inhibitors is associated with an increased risk of heavy menstrual bleeding (HMB) compared with vitamin K antagonists (VKA). Treatment with the direct oral thrombin inhibitor dabigatran appears to be associated with a reduced r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamulyák, Eva N., Wiegers, Hanke M. G., Scheres, Luuk J. J., Hutten, Barbara A., de Lange, Maria E., Timmermans, Anne, Westerweel, Peter E., Nijziel, Marten R., Kruip, Marieke J. H. A., ten Wolde, Marije, Ypma, Paula F., Klok, Frederikus A., Nieuwenhuizen, Laurens, van Wissen, Sanne, Hovens, Marcel M. C., Faber, Laura M., Kamphuisen, Pieter W., Büller, Harry R., Middeldorp, Saskia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles ‐ Thrombosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845056/
https://www.ncbi.nlm.nih.gov/pubmed/33537547
http://dx.doi.org/10.1002/rth2.12471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845056/
https://www.ncbi.nlm.nih.gov/pubmed/33537547
http://dx.doi.org/10.1002/rth2.12471

Ejemplares similares